Adam R Wolfe1, Rachel L Atkinson2, Jay P Reddy3, Bisrat G Debeb4, Richard Larson4, Li Li4, Hiroko Masuda5, Takae Brewer5, Bradley J Atkinson6, Abeena Brewster2, Naoto T Ueno5, Wendy A Woodward7. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Clinical Pharmacy Services, University of Texas MD Anderson Cancer Center, Houston, Texas. 7. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: wwoodward@mdanderson.org.
Abstract
PURPOSE: We previously demonstrated that cholesterol-lowering agents regulate radiation sensitivity of inflammatory breast cancer (IBC) cell lines in vitro and are associated with less radiation resistance among IBC patients who undergo postmastectomy radiation. We hypothesized that decreasing IBC cellular cholesterol induced by treatment with lipoproteins would increase radiation sensitivity. Here, we examined the impact of specific transporters of cholesterol (ie lipoproteins) on the responses of IBC cells to self-renewal and to radiation in vitro and on clinical outcomes in IBC patients. METHODS AND MATERIALS: Two patient-derived IBC cell lines, SUM 149 and KPL4, were incubated with low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL), or high-density lipoproteins (HDL) for 24 hours prior to irradiation (0-6 Gy) and mammosphere formation assay. Cholesterol panels were examined in a cohort of patients with primary IBC diagnosed between 1995 and 2011 at MD Anderson Cancer Center. Lipoprotein levels were then correlated to patient outcome, using the log rank statistical model, and examined in multivariate analysis using Cox regression. RESULTS: VLDL increased and HDL decreased mammosphere formation compared to untreated SUM 149 and KPL4 cells. Survival curves showed enhancement of survival in both of the IBC cell lines when pretreated with VLDL and, conversely, radiation sensitization in all cell lines when pretreated with HDL. In IBC patients, higher VLDL values (>30 mg/dL) predicted a lower 5-year overall survival rate than normal values (hazard ratio [HR] = 1.9 [95% confidence interval [CI]: 1.05-3.45], P=.035). Lower-than-normal patient HDL values (<60 mg/dL) predicted a lower 5-year overall survival rate than values higher than 60 mg/dL (HR = 3.21 [95% CI: 1.25-8.27], P=.015). CONCLUSIONS: This study discovered a relationship among the plasma levels of lipoproteins, overall patient response, and radiation resistance in IBC patients and IBC patient-derived cell lines. A more expansive study is needed to verify these observations.
PURPOSE: We previously demonstrated that cholesterol-lowering agents regulate radiation sensitivity of inflammatory breast cancer (IBC) cell lines in vitro and are associated with less radiation resistance among IBC patients who undergo postmastectomy radiation. We hypothesized that decreasing IBC cellular cholesterol induced by treatment with lipoproteins would increase radiation sensitivity. Here, we examined the impact of specific transporters of cholesterol (ie lipoproteins) on the responses of IBC cells to self-renewal and to radiation in vitro and on clinical outcomes in IBC patients. METHODS AND MATERIALS: Two patient-derived IBC cell lines, SUM 149 and KPL4, were incubated with low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL), or high-density lipoproteins (HDL) for 24 hours prior to irradiation (0-6 Gy) and mammosphere formation assay. Cholesterol panels were examined in a cohort of patients with primary IBC diagnosed between 1995 and 2011 at MD Anderson Cancer Center. Lipoprotein levels were then correlated to patient outcome, using the log rank statistical model, and examined in multivariate analysis using Cox regression. RESULTS: VLDL increased and HDL decreased mammosphere formation compared to untreated SUM 149 and KPL4 cells. Survival curves showed enhancement of survival in both of the IBC cell lines when pretreated with VLDL and, conversely, radiation sensitization in all cell lines when pretreated with HDL. In IBC patients, higher VLDL values (>30 mg/dL) predicted a lower 5-year overall survival rate than normal values (hazard ratio [HR] = 1.9 [95% confidence interval [CI]: 1.05-3.45], P=.035). Lower-than-normal patient HDL values (<60 mg/dL) predicted a lower 5-year overall survival rate than values higher than 60 mg/dL (HR = 3.21 [95% CI: 1.25-8.27], P=.015). CONCLUSIONS: This study discovered a relationship among the plasma levels of lipoproteins, overall patient response, and radiation resistance in IBC patients and IBC patient-derived cell lines. A more expansive study is needed to verify these observations.
Authors: Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha Journal: Genes Dev Date: 2003-05-15 Impact factor: 11.361
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Christa B Fuhrman; Josh Kilgore; Yvette D LaCoursiere; Christopher M Lee; Brett A Milash; Andrew P Soisson; Karen A Zempolich Journal: Gynecol Oncol Date: 2008-07 Impact factor: 5.482
Authors: Bisrat G Debeb; Wei Xu; Henry Mok; Li Li; Fredika Robertson; Naoto T Ueno; Jim Reuben; Anthony Lucci; Massimo Cristofanilli; Wendy A Woodward Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli Journal: Ann Oncol Date: 2010-07-05 Impact factor: 32.976
Authors: Erik R Nelson; Suzanne E Wardell; Jeff S Jasper; Sunghee Park; Sunil Suchindran; Matthew K Howe; Nicole J Carver; Ruchita V Pillai; Patrick M Sullivan; Varun Sondhi; Michihisa Umetani; Joseph Geradts; Donald P McDonnell Journal: Science Date: 2013-11-29 Impact factor: 47.728
Authors: Massimo Cristofanilli; Vicente Valero; Aman U Buzdar; Shu-Wan Kau; Kristine R Broglio; Ana Maria Gonzalez-Angulo; Nour Sneige; Rabiul Islam; Naoto T Ueno; Thomas A Buchholz; Sonja E Singletary; Gabriel N Hortobagyi Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Sina Bavari; Catharine M Bosio; Elizabeth Wiegand; Gordon Ruthel; Amy B Will; Thomas W Geisbert; Michael Hevey; Connie Schmaljohn; Alan Schmaljohn; M Javad Aman Journal: J Exp Med Date: 2002-03-04 Impact factor: 14.307
Authors: Matthew A Ingersoll; Dannah R Miller; October Martinez; C Brent Wakefield; Kuan-Chan Hsieh; M Vijaya Simha; Chai-Lin Kao; Hui-Ting Chen; Surinder K Batra; Ming-Fong Lin Journal: Cancer Lett Date: 2016-09-26 Impact factor: 8.679
Authors: Simona F Shaitelman; Michael C Stauder; Pamela Allen; Sangeetha Reddy; Susan Lakoski; Bradley Atkinson; Jay Reddy; Diana Amaya; William Guerra; Naoto Ueno; Abigail Caudle; Welela Tereffe; Wendy A Woodward Journal: J Cancer Date: 2017-07-05 Impact factor: 4.207